IGF-IRα Inhibitors
Common IGF-IRα Inhibitors include, but are not limited to Linsitinib-d3 CAS 867160-71-2, GSK1838705A CAS 1116235-97-2, AG 1024 CAS 65678-07-1, IGF-1R Inhibitor, PPP CAS 477-47-4 and Linsitinib-d3 CAS 867160-71-2.
IGF-IRα inhibitors belong to a specific chemical class of compounds designed to target and inhibit the activity of the insulin-like growth factor-1 receptor alpha (IGF-IRα). IGF-IRα is a cell surface receptor tyrosine kinase that plays a crucial role in mediating the cellular responses to insulin-like growth factors (IGFs). Activation of IGF-IRα by IGF ligands leads to the autophosphorylation of its tyrosine residues and subsequent initiation of downstream signaling cascades that regulate cell growth, survival, and metabolism.
IGF-IRα inhibitors work by specifically targeting the IGF-IRα receptor, interfering with its activation and downstream signaling events. By doing so, these inhibitors may modulate the cellular responses elicited by IGF-IRα activation and impact processes such as cell proliferation, differentiation, and metabolism. Research into IGF-IRα inhibitors is ongoing to unravel their precise mechanisms of action and explore their implications in understanding cellular signaling pathways. The study of IGF-IRα inhibitors contributes to a deeper comprehension of the intricate mechanisms governing growth factor-mediated cellular responses and their roles in normal physiology and disease states.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
NVP-AEW541 | 475489-16-8 | sc-507395 | 5 mg | $285.00 | ||
Acts as a selective ATP-competitive inhibitor of IGF-IRα, blocking its kinase activity and potentially inhibiting downstream signaling pathways involved in cell growth and survival. | ||||||
BMS-754807 | 1001350-96-4 | sc-507396 | 5 mg | $304.00 | ||
Inhibits both IGF-IRα and IR (Insulin Receptor) kinases, potentially suppressing signaling pathways that contribute to cell proliferation, survival, and metabolic responses. | ||||||
Linsitinib | 867160-71-2 | sc-396762 sc-396762A | 5 mg 10 mg | $146.00 $265.00 | 1 | |
Targets both IGF-IRα and IR kinases, blocking their activity and potentially disrupting downstream signaling pathways that regulate cell growth, survival, and metabolism. | ||||||
BMS-536924 | 468740-43-4 | sc-507397 | 5 mg | $285.00 | ||
Acts as a selective inhibitor of IGF-IRα kinase activity, potentially inhibiting signaling pathways related to cell growth, survival, and the metastatic potential of cancer cells. | ||||||
GSK1838705A | 1116235-97-2 | sc-364502 sc-364502A | 5 mg 50 mg | $240.00 $992.00 | ||
Targets both IGF-IRα and IR kinases, potentially inhibiting their activity and downstream signaling pathways that contribute to cell growth, survival, and metabolic responses. | ||||||
AG 1024 | 65678-07-1 | sc-205907 | 1 mg | $107.00 | 22 | |
Acts as a selective inhibitor of IGF-IRα kinase activity, potentially disrupting signaling pathways involved in cell growth, survival, and the development of certain cancers. | ||||||
GSK1904529A | 1089283-49-7 | sc-507398 | 10 mg | $321.00 | ||
Inhibits both IGF-IRα and IR kinases, potentially disrupting signaling pathways that regulate cell growth, survival, and metabolic responses. | ||||||
IGF-1R Inhibitor, PPP | 477-47-4 | sc-204008A sc-204008 sc-204008B | 1 mg 10 mg 100 mg | $138.00 $203.00 $895.00 | 63 | |
Acts as a selective IGF-IRα inhibitor, potentially inhibiting IGF-IRα kinase activity and interfering with downstream signaling pathways associated with cell growth and survival. | ||||||